Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
- PMID: 12237921
- DOI: 10.1002/cncr.10852
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
Abstract
Background: This Phase II multicenter, open-label, single-arm study evaluated the efficacy and safety of a three-drug combination of irinotecan (CPT-11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC).
Methods: Patients received repeated 21-day cycles at starting doses of paclitaxel 175 mg/m(2) administered over 3 hours, followed by carboplatin AUC of 5 over 30 minutes and CPT-11 at a starting dose level of 100 mg/m(2) over 90 minutes, all given on the first day of each cycle. Patients were evaluated for objective tumor response, time to tumor progression (TTP), survival, and safety.
Results: Forty patients were enrolled. Baseline patient characteristics included: median age 58 years (range, 32-79); 23 males and 17 females; performance status of 0 (21 patients), 1 (18 patients), or 2 (1 patient); and Stage IIIB (10 patients) and Stage IV (30 patients) disease. A median of six cycles (range, one to eight) were administered. Grade 3-4 toxicities observed in >/= 10% of the patients included neutropenia (78%), asthenia (20%), diarrhea (20%), nausea (18%), vomiting (13%), anemia (10%), and dyspnea (10%). Febrile neutropenia occurred in eight patients (20%), with one death due to neutropenic sepsis. Twelve of 38 evaluable patients had confirmed tumor responses (32%), while 21 (55%) had stable disease (including 12 patients [32%] with minor responses). Only 13% had disease progression at their initial tumor assessment. The median TTP and survival were 5.3 months (range, 0.03-6.2 months) and 12.5 months (range 0.3-28.6+ months), respectively. The one and two year survival probabilities were 0.50 (95% confidence interval [CI], 0.28-0.73) and 0.21 (95% CI, 0.0-0.67), respectively.
Conclusions: The combination of CPT-11, paclitaxel, and carboplatin can be safely administered and is active in the treatment of advanced NSCLC. Based on the favorable survival outcome, this regimen is undergoing evaluation in prospective randomized trials.
Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10852
Similar articles
-
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.J Clin Oncol. 2001 Feb 15;19(4):1078-87. doi: 10.1200/JCO.2001.19.4.1078. J Clin Oncol. 2001. PMID: 11181672 Clinical Trial.
-
Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.BMC Cancer. 2005 Jan 25;5:10. doi: 10.1186/1471-2407-5-10. BMC Cancer. 2005. PMID: 15667664 Free PMC article.
-
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.Oncologist. 2007 Jun;12(6):713-8. doi: 10.1634/theoncologist.12-6-713. Oncologist. 2007. PMID: 17602060
-
Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.Jpn J Clin Oncol. 2005 Apr;35(4):188-94. doi: 10.1093/jjco/hyi059. Jpn J Clin Oncol. 2005. PMID: 15845567 Review.
-
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.Lung Cancer. 2002 Aug;37(2):213-8. doi: 10.1016/s0169-5002(02)00081-8. Lung Cancer. 2002. PMID: 12140145 Review.
Cited by
-
Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.Br J Cancer. 2005 Nov 14;93(10):1106-11. doi: 10.1038/sj.bjc.6602827. Br J Cancer. 2005. PMID: 16251879 Free PMC article. Clinical Trial.
-
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.J Thorac Oncol. 2008 Jan;3(1):59-67. doi: 10.1097/JTO.0b013e31815e8566. J Thorac Oncol. 2008. PMID: 18166842 Free PMC article. Clinical Trial.
-
Abnormal muscle afferent function in a model of Taxol chemotherapy-induced painful neuropathy.J Neurophysiol. 2011 Jul;106(1):274-9. doi: 10.1152/jn.00141.2011. Epub 2011 May 11. J Neurophysiol. 2011. PMID: 21562188 Free PMC article.
-
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.Invest New Drugs. 2009 Aug;27(4):366-73. doi: 10.1007/s10637-008-9194-4. Epub 2008 Oct 28. Invest New Drugs. 2009. PMID: 18956138 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical